Open Access

New insights into IL‑17/IL‑23 signaling in ankylosing spondylitis (Review)

  • Authors:
    • Beatrice Andreea Chisălău
    • Laura-Ioana Crînguș
    • Florentin Ananu Vreju
    • Cristina Dorina Pârvănescu
    • Sineta Cristina Firulescu
    • Ștefan Cristian Dinescu
    • Dana Alexandra Ciobanu
    • Andrei Adrian Tica
    • Raluca Elena Sandu
    • Isabela Siloși
    • Mihail Virgil Boldeanu
    • Ioan Sabin Poenariu
    • Anca Marilena Ungureanu
    • Lidia Boldeanu
    • Andreea Lili Bărbulescu
  • View Affiliations

  • Published online on: July 9, 2020     https://doi.org/10.3892/etm.2020.8981
  • Pages: 3493-3497
  • Copyright: © Chisălău et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Ankylosing spondylitis (AS) is a progressive common autoimmune inflammatory disease, part of the spondylarthritis group, characterized, besides clinical spinal and peripheral joint inflammation, by enthesitis and new bone formation, that can lead to severe functional impairment. Beyond intensive and continuous research on the pathogenic process extensively performed in recent years, their impact on therapeutic management remains open to future development. Better knowledge of AS pathogenesis have shown results progressively and studies are being performed to advance our current understanding of the disease. It is well known that tumor necrosis factor (TNF) exerts a central role, along with interleukin‑17 (IL‑17) and interleukin‑23 (IL‑23), demonstrated by several clinical studies. Similar to other rheumatic inflammatory conditions, SA is associated with an early process of systemic bone loss, both trabecular and cortical, consecutive osteopenia, osteoporosis, and high fracture risk. Current personalized therapeutic options benefit from new published data, to prevent future complications and to improve quality of life.
View References

Related Articles

Journal Cover

October-2020
Volume 20 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chisălău BA, Crînguș L, Vreju FA, Pârvănescu CD, Firulescu SC, Dinescu ȘC, Ciobanu DA, Tica AA, Sandu RE, Siloși I, Siloși I, et al: New insights into IL‑17/IL‑23 signaling in ankylosing spondylitis (Review). Exp Ther Med 20: 3493-3497, 2020
APA
Chisălău, B.A., Crînguș, L., Vreju, F.A., Pârvănescu, C.D., Firulescu, S.C., Dinescu, Ș.C. ... Bărbulescu, A.L. (2020). New insights into IL‑17/IL‑23 signaling in ankylosing spondylitis (Review). Experimental and Therapeutic Medicine, 20, 3493-3497. https://doi.org/10.3892/etm.2020.8981
MLA
Chisălău, B. A., Crînguș, L., Vreju, F. A., Pârvănescu, C. D., Firulescu, S. C., Dinescu, Ș. C., Ciobanu, D. A., Tica, A. A., Sandu, R. E., Siloși, I., Boldeanu, M. V., Poenariu, I. S., Ungureanu, A. M., Boldeanu, L., Bărbulescu, A. L."New insights into IL‑17/IL‑23 signaling in ankylosing spondylitis (Review)". Experimental and Therapeutic Medicine 20.4 (2020): 3493-3497.
Chicago
Chisălău, B. A., Crînguș, L., Vreju, F. A., Pârvănescu, C. D., Firulescu, S. C., Dinescu, Ș. C., Ciobanu, D. A., Tica, A. A., Sandu, R. E., Siloși, I., Boldeanu, M. V., Poenariu, I. S., Ungureanu, A. M., Boldeanu, L., Bărbulescu, A. L."New insights into IL‑17/IL‑23 signaling in ankylosing spondylitis (Review)". Experimental and Therapeutic Medicine 20, no. 4 (2020): 3493-3497. https://doi.org/10.3892/etm.2020.8981